Blueprint Medicines Corp expected to post a loss of $2.54 a share - Earnings Preview

Blueprint Medicines

31/07/2023 18:06

* Blueprint Medicines Corp  BPMC.OQ   BPMC.O  is expected
to show
a rise in quarterly revenue when it reports  results on August
2. 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 24.4% increase in revenue to $45.466 million from $36.55
million a year ago, according to the mean estimate from 16
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Blueprint Medicines
Corp
is for a loss of $2.54 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Blueprint
Medicines Corp is $80​, above​ its last closing price of $63.12.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -2.69       -2.67      -2.15     Beat    19.5
 Dec. 31 2023  -2.65       -2.65      -2.65     Met     0
 Sep. 30 2022  -2.46       -2.49      -2.23     Beat    10.3​
 Jun. 30 2022  -2.25       -2.23      -2.68     Missed  -20.3
 ​​Mar.        -1.78       -1.86      -1.79     Beat    3.9
 31 2022                                                
 Dec. 31 2021  -2.48       -1.65      -5.40     Missed  -228.1
                                                        ​
 Sep. 30 2021  -1.63       -1.63      -1.94     Missed  -19.1
 Jun. 30 2021  -1.83       -1.86      -1.86     Met     0
 This summary was machine generated July 31 at 17:06 GMT.  All
figures in US dollars  unless otherwise stated